Entera Bio Ltd
F:5DT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Entera Bio Ltd
F:5DT
|
IL |
|
J
|
JD Sports Fashion PLC
OTC:JDDSF
|
UK |
Entera Bio Ltd
Entera Bio is a biotechnology company that tries to turn large drug molecules, especially peptides and proteins, into pills instead of injections. Its core work is developing oral formulations that help these medicines survive the digestive system and reach the bloodstream, which is a hard problem in drug delivery. The company mainly sells or seeks to sell its technology and drug candidates through partnerships, licensing, and future product commercialization. Its customers are usually drug makers and, if its own candidates succeed, patients and healthcare providers who need treatments for bone, hormone, and other chronic conditions that are often treated by injection today. What makes Entera’s business different is that it sits at the drug-delivery layer of the pharmaceutical value chain. Rather than inventing an entirely new drug class, it aims to make proven peptide and protein therapies easier to take and easier to use, which could make existing treatments more practical and expand how they are given.
Entera Bio is a biotechnology company that tries to turn large drug molecules, especially peptides and proteins, into pills instead of injections. Its core work is developing oral formulations that help these medicines survive the digestive system and reach the bloodstream, which is a hard problem in drug delivery.
The company mainly sells or seeks to sell its technology and drug candidates through partnerships, licensing, and future product commercialization. Its customers are usually drug makers and, if its own candidates succeed, patients and healthcare providers who need treatments for bone, hormone, and other chronic conditions that are often treated by injection today.
What makes Entera’s business different is that it sits at the drug-delivery layer of the pharmaceutical value chain. Rather than inventing an entirely new drug class, it aims to make proven peptide and protein therapies easier to take and easier to use, which could make existing treatments more practical and expand how they are given.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
